Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Pustular and erythrodermic psoriasis

Dermatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Generalised pustulation or erythroderma

Widespread sterile pustules or inflammation affecting most skin can cause temperature dysregulation, fluid and protein loss, electrolyte disturbance, infection, high-output cardiac strain and multiorgan deterioration.

Action: Arrange immediate same-day specialist assessment and likely admission, perform ABCDE and sepsis evaluation, monitor fluid balance and temperature, and avoid delay for histology or outpatient treatment trials.

Synopsis

Recognise unstable pustular or erythrodermic psoriasis, distinguish sterile inflammation from infection and drug reactions, stabilise physiological threats, and support immediate specialist-directed treatment.

  • Generalised pustular psoriasis causes widespread tender erythema studded with superficial sterile pustules; erythroderma means near-generalised inflammation and scale with systemic barrier failure.
  • NICE requires immediate same-day specialist assessment and treatment for generalised pustular psoriasis or erythroderma.
  • Perform ABCDE, full observations, core temperature, fluid balance and urine output; assess sepsis, cardiac strain and venous thromboembolism risk in parallel.
  • Take a dated timeline of psoriasis therapies, systemic corticosteroid exposure, new medicines, infection, pregnancy and adherence; do not abruptly stop an effective systemic agent without specialist direction.
  • Skin pain, mucosal erosions, dusky targets, blisters or detachment should redirect urgently toward severe drug reaction rather than being absorbed into a psoriasis label.
  • Initial tests include blood count, inflammatory markers, renal and liver profile, calcium, magnesium, albumin, cultures when infection is possible, and pregnancy testing where relevant to treatment.
  • Provide gentle emollient skin care, non-adhesive dressings, warmth and carefully monitored replacement while specialist therapy is selected; avoid irritant topicals over vast inflamed areas.
  • Systemic choice is consultant-led: NICE supports ciclosporin when rapid control is needed and acitretin for pustular forms, with phenotype, comorbidity, pregnancy potential and organ function governing selection.

Key red flags

Fever, tachycardia, hypotension, reduced urine output, confusion, shivering, oedema or breathlessness indicates physiological compromise and requires emergency assessment.

Skin pain, dusky areas, blisters, epidermal detachment, mucosal erosions or a recent high-risk medicine suggests severe cutaneous adverse reaction rather than assuming psoriasis.

Purpura, rapidly spreading warmth, focal fluctuance, positive sepsis features or disproportionate pain raises concern for invasive infection requiring immediate antimicrobial and surgical assessment.

Pregnancy with generalised pustulation is a specialist emergency because maternal electrolyte disturbance and placental or fetal complications may occur.

Generalised sterile pustules

Sheets of small superficial non-follicular pustules develop on hot tender inflamed skin and may merge. Pustule contents are not assumed infectious, but fever and neutrophilia cannot distinguish sterile inflammation from sepsis.

Erythrodermic inflammation

Most of the skin becomes inflamed, warm and scaly, sometimes obscuring original plaque borders. In deeply pigmented skin, widespread darkening, violaceous change and heat may be more apparent than redness.

Barrier failure

Shivering, oedema, thirst, oliguria, hypotension, confusion or temperature abnormality indicates physiologic loss through diseased skin. Record weight and input-output as well as the rash extent.

Drug-reaction clues

New medicine exposure, facial oedema, mucosal disease, targetoid or dusky lesions, skin pain, blistering, eosinophilia or internal-organ injury makes a severe cutaneous adverse reaction more likely.

Investigation priorities

01
First-line physiological assessmentFirst stepFirst line

Detect shock, respiratory compromise, temperature disturbance, acute kidney injury and fluid loss immediately.

Management branches

ImmediateSame-day admission and stabilisation

Generalised pustulation or near-total inflammation, particularly with systemic symptoms or abnormal observations.

  1. Call dermatology and acute medical services immediately, use ABCDE, establish monitoring and assess whether higher-acuity care is required.
  2. Measure input-output, urine, electrolytes, albumin, temperature and weight; give carefully titrated fluid and electrolyte replacement with cardiac and renal reassessment.
  3. Use bland emollient, gentle handling, non-adhesive dressings and a thermally controlled environment; avoid stripping scale or applying irritant active products across extensive skin.
  4. Take indicated cultures and start sepsis treatment promptly when infection is suspected; obtain analgesia, nutrition, thromboprophylaxis assessment and medication reconciliation.
DischargePrevent rebound and readmission

Physiology stable, skin improving and a safe ongoing plan agreed.

  1. Document the most likely trigger, medicines stopped or continued, laboratory recovery, current systemic regimen, monitoring owner and exact escalation symptoms.
  2. Provide sufficient topical and systemic treatment, written dosing and rapid access if pustules, diffuse inflammation, fever or reduced urine recur.

Key medicines

Ciclosporin for rapid specialist controlNICE uses 2.5 to 3 mg/kg/day orally in 2 divided doses; increase towards 5 mg/kg/day after 4 weeks only for non-response, or earlier when rapid control is necessary in severe unstable disease.Check blood pressure, renal function, potassium, magnesium, infection, malignancy risk and interacting medicines; avoid unplanned combination immunosuppression and reduce to the lowest effective dose.
Acitretin for pustular psoriasisNICE targets 25 mg orally once daily using incremental dosing and permits escalation to a maximum 50 mg daily only when no other treatment option is available; assess response by 4 months.Highly teratogenic: follow the current MHRA pregnancy-prevention programme, including contraception and testing for 3 years after stopping where pregnancy is possible; monitor lipids, liver and mucocutaneous toxicity.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG153: immediate referral and systemic psoriasis treatment
  • British Association of Dermatologists: psoriasis overview
  • British Association of Dermatologists: SJS and TEN
  • Neoral capsules Summary of Product Characteristics
  • MHRA: oral retinoid pregnancy-prevention materials

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Focal infection clue

Asymmetric rapidly advancing warmth, focal purulence, crepitus, marked tenderness or haemodynamic sepsis warrants immediate infection and surgical pathways; inflammatory psoriasis does not protect against invasive infection.

Coordinate dermatology, primary care, pharmacy and maternity or other specialties; never leave a systemic medicine without a named prescriber and monitoring schedule.